Duan WR
No ORCID on file
· 5 papers in corpus
· active 2017-2018
Study types
- article 3
- rct 1
Condition tags
- endometriosis 3
- dysmenorrhea 2
- chronic_pelvic_pain 2
- dyspareunia 1
Top journals
Frequent coauthors
- Carr BR 4
- Joseph Ng 4
- Simon JA 4
- Watts Nb 4
- Archer Df 4
- Abrão Ms 3
- Johnson NP 3
- Chwalisz K 3
- Diamond MP 3
- Brittany Schwefel 3
2018
ObjectiveTo evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyoma…
article
2018
The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies we…
article
2018
OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…
article
2018
We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the c…
rct
2017
BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…